Shir sannadeedka 2017 ee Ururka Cudurrada Beerka ee Maraykanka, daraasad ballaadhan oo indho-indhayn ah ayaa sheegay in isticmaalka daawaynta tooska ah ee ka hortagga fayraska (DAA) si loo ciribtiro fayraska cagaarshow C (HCV) ay yarayn karto halista kansarka beerka 71%. Bukaannada qaba cirrhosis iyo cirrhosis-ka, khatarta kansarka beerka waa la dhimay. Dalka Maraykanka, badi kansarka beerka ee asaasiga ahi waxa uu ku dhacaa dadka qaba HCV. Cilmi-baarayaal ka tirsan Jaamacadda Washington waxay qiyaaseen in ciribtirka HCV uu baabi'in karo ama ugu yaraan si weyn hoos ugu dhigi karo khatarta kansarka beerka. Si kastaba ha ahaatee, kahor ciribtirka HCV, bukaanku waxaa laga yaabaa inuu ku dhacay cirrhosis ama fibrosis beerka. Xataa haddii ciribtirka HCV laga yaabo inuu aad u daahdo, weli waxaa jirta khatarta ah inuu ku dhaco kansarka beerka. Intaa waxaa dheer, daraasadihii ugu dambeeyay waxay soo jeedinayaan in khatarta kansarka beerka ee bukaannada HCV-ku-dhacsan ee helay daaweynta cusub ee DAA ay weli sii korodhay. Cilmi-baadhayaashu waxay falanqeeyeen 62,051 bukaan oo qaba caabuqa HCV kuwaas oo helay 83,695 daawaynta fayraska. Ka dib 180 maalmood oo daawaynta ka hortagga fayraska, celcelis ahaan 3,271 kansar beerka cusub ayaa dhacay intii lagu jiray dabagalka 6.1 sano. Bukaanka qaba cirrhosis ee ku guuldareystay daaweynta waxay lahaayeen dhacdooyinka ugu sarreeya ee kansarka beerka (3.25 / 100 qof-sano), oo ay ku xigto bukaannada qaba cirrhosis kuwaas oo helay jawaab celin fayras ah (SVR) (1.97 / 100 qof-sano), iyo bukaanada aan lahayn cirrhosis laakiin daawaynta ku guuldareysatay (0.87 / 100 qof-sano) iyo bukaanada aan lahayn cirrhosis kuwaas oo helay SVR (0.24 / 100 qof-sano). Falanqaynta kala duwan ayaa muujisay in ka dib marka la isku hagaajiyo isku-dhafka suurtagalka ah, SVR waxay si weyn ula xiriirtay khatarta hoose ee kansarka beerka, iyada oo aan loo eegin haddii daaweynta DAA (aHR = 0.29), DAA oo ay weheliso daaweynta interferon (aHR = 0.48), ama daaweynta interferon kaliya (aHR) = 0.32).
Cilmi-baadhayaashu waxay ku nuuxnuuxsadeen in cilmi-baaris lagu sameeyay Shirweynaha Cudurka Beerka ee Yurub sannadkii hore ay soo jeedisay in bukaannada HCV ee lagu daaweeyay DAA ay u muuqdaan inay leeyihiin heerka soo noqnoqda ee kansarka beerka. Natiijadan ayaa ah mid aad u muran badan, sababtoo ah xiriirka ka dhexeeya HCV iyo kansarka beerka ayaa soo jeedinaya in ciribtirka HCV ay tahay in la yareeyo khatarta kansarka beerka maaha in la kordhiyo halista kansarka beerka. Gabagabadii daraasaddan indho-indhaynta ah ayaa aad loo hubaa in dabar-goynta DAA ee HCV ay hoos u dhigi karto halista kansarka beerka 71%, taas oo soo jeedinaysa in aan loo baahnayn in laga werwero ciribtirka HCV si loo kordhiyo khatarta kansarka beerka. Ciribtirka HCV waa in la yareeyo khatarta kansarka beerka.
